[LONDON, UK, 5th September 2024] We are excited to announce that Dan Ryalls has been appointed as Chief Financial Officer (CFO) of Veramed. Dan’s strategic leadership will play a pivotal role in guiding Veramed’s growth trajectory as the company expands services and broadens its global footprint.
Dan Ryalls is an accomplished CFO with a proven track record spanning industries such as FMCG, Manufacturing, Supply Chain, Retail, and SaaS platforms. Most recently, he spent 10 years as the CFO for a Global Marketing Outsourcing agency in which he led the MBO in 2014. With extensive international exposure across APAC, Europe, and North America, Dan brings valuable experience in managing multi-jurisdictional growth and operating in dynamic environments.
Dan will leverage his expertise in global finance management, financial planning and analysis, and financial governance to support Veramed’s business growth and enhance operational efficiency.
“We are thrilled to welcome Dan Ryalls to the Veramed team as Chief Financial Officer,” said Matt Jones, CEO and Co-Founder of Veramed. “Dan’s extensive experience and strategic vision will be instrumental in ensuring the sustainable growth and development of Veramed as we navigate the evolving landscape of our industry.“
Dan Ryalls’ appointment as CFO highlights Veramed’s dedication to fortifying its financial leadership and underscores Veramed’s commitment to delivering quality outcomes for patients, sponsors and internal stakeholders.
About Veramed
Veramed is a high-performing partner for statistical consultancy, data management, clinical trial reporting and automation, DMC services, and evidence and value generation. Veramed is a pioneering CRO that is redefining intelligent healthcare decision-making. The talented Veramed team offers pharma and biotech clients flexible, tailored biometrics solutions that can be scaled and adapted along with the needs of their organization, from initial study design to submission and beyond. Veramed is also known for taking up industry-leading involvement in projects such as the recent PHUSE/CDISC Dataset-JSON initiative.
Veramed is uniquely practitioner-led, and passionate about making a difference to patient communities around the world by moving the needle on the speed, quality and effectiveness of pharma and biotech pipeline delivery.
Veramed was awarded “Best Contract Research Organization – Specialist Providers” at the 18th Annual Scrip Awards in 2022 and certified as a B Corp for the first time in 2020. For more details, see the Veramed website at: https://www.veramed.co.uk/
